These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 28903441)

  • 1. Loss of steroid hormone receptors is common in malignant pleural and peritoneal effusions of breast cancer patients treated with endocrine therapy.
    Schrijver WAME; Schuurman K; van Rossum A; ; Peeters T; Ter Hoeve N; Zwart W; van Diest PJ; Moelans CB
    Oncotarget; 2017 Aug; 8(33):55550-55561. PubMed ID: 28903441
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Receptor Conversion in Distant Breast Cancer Metastases: A Systematic Review and Meta-analysis.
    Schrijver WAME; Suijkerbuijk KPM; van Gils CH; van der Wall E; Moelans CB; van Diest PJ
    J Natl Cancer Inst; 2018 Jun; 110(6):568-580. PubMed ID: 29315431
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discordance in ERα, PR and HER2 receptor status across different distant breast cancer metastases within the same patient.
    Hoefnagel LD; van der Groep P; van de Vijver MJ; Boers JE; Wesseling P; Wesseling J; ; van der Wall E; van Diest PJ
    Ann Oncol; 2013 Dec; 24(12):3017-23. PubMed ID: 24114857
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metastatic breast carcinoma in pleural fluid: Correlation of receptor and HER2 status with the primary carcinoma-a pilot study.
    Francis IM; Alath P; George SS; Jaragh M; Al Jassar A; Kapila K
    Diagn Cytopathol; 2016 Dec; 44(12):980-986. PubMed ID: 27666130
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic value of estrogen receptor α and progesterone receptor conversion in distant breast cancer metastases.
    Hoefnagel LD; Moelans CB; Meijer SL; van Slooten HJ; Wesseling P; Wesseling J; Westenend PJ; Bart J; Seldenrijk CA; Nagtegaal ID; Oudejans J; van der Valk P; van Gils CH; van der Wall E; van Diest PJ
    Cancer; 2012 Oct; 118(20):4929-35. PubMed ID: 22415862
    [TBL] [Abstract][Full Text] [Related]  

  • 6. FOXA1 levels are decreased in pleural breast cancer metastases after adjuvant endocrine therapy, and this is associated with poor outcome.
    Schrijver W; Schuurman K; van Rossum A; Droog M; Jeronimo C; Salta S; Henrique R; Wesseling J; Moelans C; Linn SC; van den Heuvel M; van Diest P; Zwart W
    Mol Oncol; 2018 Nov; 12(11):1884-1894. PubMed ID: 29972720
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Proteomics on malignant pleural effusions reveals ERα loss in metastatic breast cancer associates with SGK1-NDRG1 deregulation.
    Mayayo-Peralta I; Debets DO; Prekovic S; Schuurman K; Beerthuijzen S; Almekinders M; Sanders J; Moelans CB; Saleiro S; Wesseling J; van Diest PJ; Henrique R; Jerónimo C; Altelaar M; Zwart W
    Mol Oncol; 2024 Jan; 18(1):156-169. PubMed ID: 37854018
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hormone Receptor Status and HER2 Expression in Primary Breast Cancer Compared With Synchronous Axillary Metastases or Recurrent Metastatic Disease.
    Rossi S; Basso M; Strippoli A; Dadduzio V; Cerchiaro E; Barile R; D'Argento E; Cassano A; Schinzari G; Barone C
    Clin Breast Cancer; 2015 Oct; 15(5):307-12. PubMed ID: 25922284
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Benefits of using the cell block method to determine the discordance of the HR/HER2 expression in patients with metastatic breast cancer.
    Nakayama Y; Nakagomi H; Omori M; Inoue M; Takahashi K; Maruyama M; Takano A; Furuya K; Amemiya K; Ishii E; Oyama T
    Breast Cancer; 2016 Jul; 23(4):633-9. PubMed ID: 25968348
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discordant expression of hormone receptors and HER2 in breast cancer. A retrospective comparison of primary tumors with paired metachronous recurrences or metastases.
    Arapantoni-Dadioti P; Valavanis C; Gavressea T; Tzaida O; Trihia H; Lekka I
    J BUON; 2012; 17(2):277-83. PubMed ID: 22740206
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reliability of Her2/neu, estrogen receptor, and progesterone receptor testing by immunohistochemistry on cell block of FNA and serous effusions from patients with primary and metastatic breast carcinoma.
    Shabaik A; Lin G; Peterson M; Hasteh F; Tipps A; Datnow B; Weidner N
    Diagn Cytopathol; 2011 May; 39(5):328-32. PubMed ID: 21488175
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Steroid hormone receptors as targets for the therapy of breast and prostate cancer--recent advances, mechanisms of resistance, and new approaches.
    Hoffmann J; Sommer A
    J Steroid Biochem Mol Biol; 2005 Feb; 93(2-5):191-200. PubMed ID: 15860262
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Estrogen receptor beta--an independent prognostic marker in estrogen receptor alpha and progesterone receptor-positive breast cancer?
    Maehle BO; Collett K; Tretli S; Akslen LA; Grotmol T
    APMIS; 2009 Sep; 117(9):644-50. PubMed ID: 19703124
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discordance and Conversion Rates of Progesterone-, Estrogen-, and HER2/neu-Receptor Status in Primary Breast Cancer and Brain Metastasis Mainly Triggered by Hormone Therapy.
    Timmer M; Werner JM; Röhn G; Ortmann M; Blau T; Cramer C; Stavrinou P; Krischek B; Mallman P; Goldbrunner R
    Anticancer Res; 2017 Sep; 37(9):4859-4865. PubMed ID: 28870906
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metastatic salivary duct carcinoma in cardiac and pleural effusions: A case report with immunocytochemical analysis for androgen receptor and HER2.
    Ito H; Ishida M; Sando K; Okano K; Ebisu Y; Fujisawa T; Iwai H; Tsuta K
    Mol Clin Oncol; 2019 Jan; 10(1):78-82. PubMed ID: 30655980
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differences in clinical importance of Bcl-2 in breast cancer according to hormone receptors status or adjuvant endocrine therapy.
    Honma N; Horii R; Ito Y; Saji S; Younes M; Iwase T; Akiyama F
    BMC Cancer; 2015 Oct; 15():698. PubMed ID: 26472348
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Steroid receptors in pleural effusions of advanced breast cancer patients.
    Branković-Magić M; Nesković-Konstantinović Z; Nikolić-Vukosavljević D; Spuzić I
    Int J Biol Markers; 1995; 10(3):143-8. PubMed ID: 8551056
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Prognostic Impact of Hormonal Receptor and HER-2 Expression Discordance in Metastatic Breast Cancer Patients.
    Yang Z; Li N; Li X; Lei L; Wang X
    Onco Targets Ther; 2020; 13():853-863. PubMed ID: 32099389
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Altered expression of metastasis-associated and regulatory molecules in effusions from breast cancer patients: a novel model for tumor progression.
    Davidson B; Konstantinovsky S; Nielsen S; Dong HP; Berner A; Vyberg M; Reich R
    Clin Cancer Res; 2004 Nov; 10(21):7335-46. PubMed ID: 15534110
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Folate Receptor Alpha Immunohistochemistry in Cytology Specimens of Metastatic Breast Carcinoma.
    Sheikh UN; Cohen C; Siddiqui MT
    Acta Cytol; 2015; 59(4):298-304. PubMed ID: 26413911
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.